Pharma Focus Asia

Novartis shells out $8.7 billion to buy AveXis

Monday, April 09, 2018

Novartis said on Monday it plans to buy AveXis (AVXS.O) for $218 per share in a cash deal totaling $8.7 billion as the Swiss drugmaker adds a company whose top drug hopeful, for spinal muscular atrophy, has U.S. breakthrough therapy designation.

Novartis is flush with cash, having just agreed to sell its stake in a consumer healthcare joint venture for $13 billion to GlaxoSmithKline (GSK.L).

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024